Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences
Beijing, 100021, China
NCT Number: NCT02688036
The purpose of this study is to determine whether hypofractionated concurrent chemo-radiotherapy has the same efficiency as conventionally fractionated concurrent chemo-radiotherapy in Limited Disease Small Cell Lung Cancer.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 3
Beijing, 100021, China
For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm. While 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm. Both survival and toxicity of the two arms will be observed and compared.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm.
For patients with Limited Disease Small Cell Lung Cancer, 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm.
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Incidence of tumor recurrence in local or regional area
Time frame: 2 year
Incidence of radiotherapy and chemotherapy induced toxicities assessed by CTCAE v 4.0
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Other
Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07161882
Adenocarcinoma, Bronchial Neoplasms
Algiers, Algiers Province, Algeria
View Trial DetailsNCT03212404
Adenocarcinoma, Adenoma
Wollongong, New South Wales, Australia
View Trial DetailsNCT05461430
Adenocarcinoma, Adenoma
Oakland, California, United States
View Trial DetailsNCT03554473
Bronchial Neoplasms, Carcinoma
Bethesda, Maryland, United States
View Trial Details